AI and Neurological Rare & Neuroimmune Diseases ── 2026-11-12
New papers on neurological rare and neuroimmune diseases and AI, collected from journal feeds, PubMed (searched across all journals) and OpenAlex (a public index used instead of Google Scholar), judged by Jev (an AI that makes language judgements): original research, AI central, which of 9 disease groups, treatment or trials, and then ranked by importance up to a daily limit. Journals are not filtered by impact factor; each paper shows its journal's IF-equivalent (OpenAlex two-year mean citedness) and the date of that value. Each entry shows the full original abstract.
Read by disease: Basic research(2) · ALS(0) · Parkinson's(2) · Hereditary neurodegeneration(0) · Neuromuscular(0) · Multiple sclerosis(1) · NMOSD/MOGAD(0) · Myasthenia gravis(0) · Autoimmune encephalitis/CIDP/GBS(0)
Neurodegeneration and neuroimmunology research and AI
- Abstract
Background: Machine learning in tremor time-series analysis has so far been applied to differentiate tremor disorders. Respective analytical approaches can similarly be geared to explore therapeutic interventions, which conventionally are assessed by their induced amplitude changes. This may overlook subtle signal alterations. Feature-based machine learning offers the potential to explore much more granular tremor signal changes induced by therapeutic interventions.
Objective: To investigate multidimensional time-series signal changes associated with tremor-modulating interventions, and to identify shared and distinct intervention-specific patterns across tremor conditions.
Methods: Sixty-six participants (Essential Tremor (ET): propranolol n = 13, deep brain stimulation (DBS) n = 10; Parkinson’s Disease (PD): levodopa n = 23; enhanced Physiological Tremor (ePT): caffeine n = 20) were assessed in therapeutic OFF and ON states using high-resolution tri-axial accelerometry. In addition to established tremor characteristics, advanced time-series features were extracted from raw recordings. Machine Learning (ML) approaches, including ensemble classification and Principal Component Analysis (PCA), were applied to detect intervention-related changes.
Results: Significant clinical and signal-based intervention effects were observed across cohorts with the strongest tremor suppression following DBS in ET and expected tremor enhancement following caffeine in ePT. While amplitude-related features decreased consistently after therapeutic interventions, dopaminergic treatment in PD was additionally associated with changes in frequency-related characteristics. Caffeine-induced tremor modulation formed a distinct multidimensional signal pattern, whereas therapeutic interventions showed partially overlapping effects. No single feature consistently characterized successful tremor modulation across all interventions.
Conclusion: Feature-based ML reveals intervention-specific tremor patterns beyond conventional measures, supporting data-driven approaches for objective tremor characterization.
Journal IF-equivalent: 3.7 (OpenAlex 2-year mean citedness, value as of 2026-11-11, retrieved 2026-11-12; not the official Clarivate IF)Reference: Köhler L, Müller J, Chen YS, Selzam V, Häring V, Volkmann J, et al. Multi-dimensional signal exploration on the effect of tremor interventions. Front Neurol. 2026 Nov 10;17:1954245. doi:10.3389/fneur.2026.1954245.Checked: Abstract only - Abstract
In axons, mitochondrial transport is essential for neuronal function and survival, and its disruption is increasingly recognized as an early pathological hallmark in multiple neurodegenerative diseases. Despite its importance, quantitative analysis of mitochondrial transport dynamics remains challenging due to complex and heterogeneous motility patterns and reliance on labor-intensive manual tracking methods. Here, we present a deep learning-assisted framework for semiautomated quantification of mitochondrial axonal transport. Using time-lapse confocal imaging of individual in vivo axons in the well-established Drosophila nervous system, we comprehensively validated transport parameters, including displacement and velocity. We further assessed the fidelity of our method in recapitulating expert-derived measurements and its potential to overcome the limitations of conventional manual tracking. Notably, our framework enables detailed characterization of dynamic behaviors during transport, including intensity-based variations and concurrent morphological changes within individual mitochondria, potentially reflecting mitochondrial physiological states that were difficult to resolve with traditional approaches. Collectively, our study establishes the feasibility of next-generation analysis for axonal transport and highlights its potential to uncover previously inaccessible aspects of mitochondrial dynamics, providing a scalable and objective framework for investigating mitochondrial in vivo transport dysfunction in neurodegenerative disease models.
Journal IF-equivalent: 6.2 (OpenAlex 2-year mean citedness, value as of 2026-11-11, retrieved 2026-11-12; not the official Clarivate IF)Reference: Park JY, Chae M, Sung H. Leveraging Deep Learning to Reveal Fine-Scale In Vivo Mitochondrial Dynamics and Axonal Transport. Yale J Biol Med. 2026 Nov 4;99(3):558-75. doi:10.59249/zsdt8892.Checked: Abstract only
See all 2 Basic research papers →
ALS: treatment, trials and AI
No new qualifying paper for this issue.
Parkinson's disease and parkinsonism: treatment, trials and AI
- Abstract
Systematic review and meta-analysis of supervised machine-learning and deep-learning models that predict a future diagnosis of Parkinson's disease in people without the disease, analysed in two strata: at-risk cohorts (mainly isolated REM sleep behaviour disorder, B1) and general or clinical populations (B2). The protocol and search strategy were frozen and approved by the supervisor on 13 October 2026, before the searches were run on 21-22 October 2026. This registration is retrospective; the frozen files are attached unchanged, and all later amendments are listed in the attached protocol document.
Journal IF: unknown (could not be matched)Reference: [No authors listed]. Machine learning models for predicting future Parkinson's disease: systematic review and meta-analysis. Open Science Framework. [Epub ahead of print]. doi:10.17605/osf.io/qgazv.Checked: Abstract only - Abstract
BACKGROUND: To develop and validate a T1-weighted imaging (T1WI)-based radiomic signature and integrate it with clinical features to construct a combined model for the early identification of cognitive decline in Parkinson's disease (PD). METHODS: We retrospectively analyzed data from 233 PD patients, including 182 from the Parkinson's Progression Markers Initiative (PPMI) and 51 from the National Alzheimer's Coordinating Center (NACC). Based on baseline Montreal Cognitive Assessment (MoCA) scores, patients were classified into those with normal cognition (PD-NC) and those with mild cognitive impairment (PD-MCI). The PPMI cohort was randomly divided into training (n = 127) and test (n = 55) sets at a 7:3 ratio, while the NACC cohort served as an external validation set (n = 51). Radiomic features were extracted from T1WI of the bilateral basal ganglia (globus pallidus, putamen) and bilateral thalamus. After dimensionality reduction, a radiomic model was constructed. Independent clinical predictors were identified and integrated with the radiomic signature to establish a combined model. Model performance was evaluated using receiver operating characteristic (ROC) curves, confusion matrices, and F1-scores. SHapley Additive exPlanations (SHAP) was employed to interpret model outputs. RESULTS: The radiomic model achieved area under the curve (AUC) values of 0.809, 0.777, and 0.776 in the training, test, and external validation sets, respectively. Multivariable regression identified the Geriatric Depression Scale (GDS) score (odds ratio [OR] = 1.41, P = 0.005) and resting tremor (OR = 4.11, P = 0.036) as independent predictors. The combined model incorporating these clinical factors with the radiomic signature yielded significantly improved AUCs of 0.848 (95% CI: 0.774-0.906), 0.796 (95% CI: 0.666-0.893), and 0.812 (95% CI: 0.628-0.925) across the three datasets, outperforming either model alone. Among the 13 retained radiomic features, texture features were predominant (69.2%). SHAP analysis confirmed that the Rad-score was the most influential predictor. CONCLUSION: The combined model integrating T1WI-based radiomic features from the bilateral basal ganglia (globus pallidus, putamen)-thalamus with clinical characteristics demonstrates robust predictive capability for cognitive decline in PD. This approach offers valuable support for early intervention and precision management in clinical practice.
Journal IF-equivalent: 3.8 (OpenAlex 2-year mean citedness, value as of 2026-10-15, retrieved 2026-10-16; not the official Clarivate IF)Reference: Jian Y, Shi H, Hu T, Zhou S, He X, Tao D, et al. Interpretable radiomics signature of the basal ganglia-thalamic circuitry for predicting PD-MCI: a multi-center study with external validation. BMC Med Imaging. 2026 Aug 12;26(1):593. doi:10.1186/s12880-026-02668-7.Checked: Abstract only
See all 2 Parkinson's papers →
Hereditary neurodegenerative diseases: treatment, trials and AI
No new qualifying paper for this issue.
Neuromuscular diseases (muscular dystrophy, SMA): treatment, trials and AI
No new qualifying paper for this issue.
Multiple sclerosis: treatment, trials and AI
- Abstract
Multiple sclerosis (MS) presents a clinico-radiological paradox in which patients with similar magnetic resonance imaging lesion burdens may exhibit different levels of neurological disability. This study investigates whether combining clinical subsystem scores with structural lesion measurements improves the characterization of disability-defined patient groups. Data from 59 patients were categorized as resilient (EDSS ≤ 3.0; n = 42) or vulnerable (EDSS > 3.0; n = 17). Random Forest, Linear Support Vector Machine, and L1-regularized Logistic Regression classifiers were evaluated using five-fold stratified cross-validation. The corresponding ROC-AUC scores were 0.6130, 0.6819, and 0.7271, respectively. SHAP analysis identified cerebellar and pyramidal scores as influential predictors, while lesion volume contributed additional information. Counterfactual explanations generated using DiCE produced 22 valid alternatives across vulnerable patient profiles, with lesion volume modified in all alternatives. These exploratory findings suggest that combining clinical subsystem measurements with structural lesion burden may help characterize disability heterogeneity in MS. Larger independent datasets and further validation are required before clinical application.
Journal IF-equivalent: 0.3 (OpenAlex 2-year mean citedness, value as of 2026-11-11, retrieved 2026-11-12; not the official Clarivate IF)Reference: Reddy Adla A, MP S. Beyond Lesion Burden: An Explainable Machine Learning Framework for Characterizing Clinical Resilience in Multiple Sclerosis. IJSR. 2026 Nov 10 [Epub ahead of print]. doi:10.21275/sr261103212002.Checked: Abstract only
See all 1 Multiple sclerosis papers →
NMOSD and MOGAD: treatment, trials and AI
No new qualifying paper for this issue.
Myasthenia gravis: treatment, trials and AI
No new qualifying paper for this issue.
Autoimmune encephalitis, CIDP and Guillain-Barre syndrome: treatment, trials and AI
No new qualifying paper for this issue.